All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Mutation testing in AML:
What you need to know

with Charles Craddock, Ralph Hills, and Gail Roboz

Wednesday, April 23, 2025
17:30-18:30 BST

Register now

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-01-09T15:02:24.000Z

PRGN-3006 is granted Orphan Drug Designation for relapsed or refractory acute myeloid leukemia by the U.S. FDA

Jan 9, 2020
Share:

Bookmark this article

The U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to PRGN-3006 for the treatment of patients with relapsed or refractory (RR) acute myeloid leukemia (AML).1,2 PRGN-3006 is an investigational therapy which uses a proprietary UltraCAR-T™ therapeutic platform to reduce the time to manufacture chimeric antigen receptor (CAR) T cells, enabling the administration of CAR T cells one day after non-viral gene transfer. PRGN-3006 UltraCAR-T is a multigenic CAR T-cell product, co-expressing a CD33 CAR and membrane-bound interleukin-15 (mbIL15), together with a ‘kill switch’. CD33 CAR precisely targets malignant cells expressing CD33, while expression of mbIL15 allows the elimination of ex vivo expansion of T cells prior to cell administration. The kill switch provides a mechanism for selective depletion of PRGN-3006 post-administration in order to improve therapeutic control.

There is an ongoing trial of PRGN-3006 (NCT03927261), in patients with RR AML and high-risk myelodysplastic syndromes, which has completed enrolment of the first cohort and initial data is expected later this year. Preclinical data on PRGN-3006 were presented at the 61st American Society for Hematology Annual Meeting & Exposition, in Orlando, US.3

Orphan drug status is granted to medicines aimed at treating, detecting or preventing rare diseases or disorders affecting < 200,000 people in the US. This status grants certain incentives such as a seven-year exclusivity marketing period, applications for funding for phase I and II clinical trials, reduced market application filing fees and rapid regulatory processing later on.

  1. Healio. FDA grants orphan drug designation to PRGN-3006 for AML.https://www.healio.com/hematology-oncology/leukemia/news/online/%7B3c7aeba4-ac5c-4c00-95f0-ee4148a44f31%7D/fda-grants-orphan-drug-designation-to-prgn-3006-for-aml . Published; January 6 2020, [Accessed 2020 Jan 08]
  2. Biospace. Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML). https://www.biospace.com/article/releases/precigen-receives-fda-orphan-drug-designation-for-prgn-3006-ultracar-t-in-patients-with-acute-myeloid-leukemia-aml-/ Published; January 6 2020, [Accessed 2020 Jan 08]
  3. Chan T. et al., Preclinical Characterization of Prgn-3006 Ultracar-T™ for the Treatment of AML and MDS: Non-Viral, Multigenic Autologous CAR-T Cells Administered One Day after Gene Transfer; 2019 Dec 08. Poster Abstract #2660: ASH 61st Annual Meeting & Exposition, Orlando, FL

Newsletter

Subscribe to get the best content related to AML delivered to your inbox